John A. Josey, Ph.D. Peloton Therapeutics, Inc. presents “Targeting HIF-2: Myth or Reality? A First-In-Class HIF-2 Antagonist for the Treatment of clear cell Renal Cell Carcinoma: PT2385” at the 14th International Kidney Cancer Symposium.
John A. Josey, Ph.D. Peloton Therapeutics, Inc. presents “Targeting HIF-2: Myth or Reality? A First-In-Class HIF-2 Antagonist for the Treatment of clear cell Renal Cell Carcinoma: PT2385” at the 14th International Kidney Cancer Symposium.